RecruitingPhase 2NCT07111065
45
studies recruiting now
as of 7 Sept 2026
188
studies registered in total
as of 7 Sept 2026
13
countries with a recruiting site
as of 7 Sept 2026
2 Sept 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT00017914
Adult and Juvenile Myositis
RecruitingPhase 2 / Phase 3NCT06154252
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RecruitingPhase 1 / Phase 2NCT07800871
FT839 in Autoimmune Diseases
RecruitingPhase 3NCT06698796
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 45 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Polymyositis study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Polymyositis
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
2 approved treatments and 6 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Cortisone Acetate (Cortate)Approved: Prednisone (Cortan)
Phase 3Ustekinumab (Stelara)
Phase 2Siponimod (Mayzent)
Phase 2Tocilizumab (Actemra roactemra)
Phase 2Infliximab (Flixabi)
Phase 2Methimazole (Favistan)
Phase 2Zetomipzomib
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).